Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. (CLRB) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CLRB · as of Sep 30, 2025
Ownership Breakdown
22
Institutional Holders
▲ 3 vs Q2
$1.91M
Total Inst. Value
▲ $1.17M vs Q2
3.19M
Shares Outstanding
freeFloat 94.33%
416,651
13F Shares Held
▲ 313,254 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CLRB largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BARCLAYS PLC pharmaceutical preparations | 120.5K | 7.49% | 7.49% | $257.86M | Mar 19, 2026 | NEW |
BLEICHROEDER LP pharmaceutical preparations | 100.0K | 3.16% | 3.16% | $560.00M | Nov 14, 2025 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 65.2K | 2.06% | 2.06% | $364.96M | Nov 7, 2025 | ▲ 8.8K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 24.9K | 78.75% | 78.75% | $139.44M | Nov 13, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 24.9K | 78.72% | 78.72% | $139.41M | Nov 12, 2025 | ▲ 10.5K |
DRW SECURITIES, LLC pharmaceutical preparations | 21.1K | 66.73% | 66.73% | $118.17M | Nov 14, 2025 | NEW |
CITADEL ADVISORS LLC pharmaceutical preparations | 18.5K | 58.59% | 58.59% | $103.75M | Nov 14, 2025 | NEW |
DIMENSIONAL FUND ADVISORS LP pharmaceutical preparations | 13.0K | 41.22% | 41.22% | $72.98M | Nov 12, 2025 | NEW |
SEQUOIA FINANCIAL ADVISORS, LLC pharmaceutical preparations | 10.8K | 34.10% | 34.10% | $60.38M | Oct 29, 2025 | NEW |
RIVERVIEW CAPITAL ADVISERS, LLC pharmaceutical preparations | 10.4K | 32.84% | 32.84% | $50.05M | Nov 12, 2025 | ▼ 116 |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
7
Increased
+20.2K shares7
New Positions
first time holders3
Decreased
−2.9K shares5
Sold Out
fully exitedNet shares change (top 50)
+17.4K
+20.2K / −2.9K
Net new holders
+6
7 new / 5 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CLRB insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Longcor Jarrod Chief Operating Officer | May 7, 2026 | Purchase | 26,040 | $2.88 | $75.0K | 36.1K | Form 4 ↗ |
Longcor Jarrod Chief Operating Officer | May 7, 2026 | Purchase | 8,680 | $2.88 | $25.0K | 20.5K | Form 4 ↗ |
CARUSO JAMES V Chief Executive Officer | May 7, 2026 | Purchase | 26,040 | $2.88 | $75.0K | 36.1K | Form 4 ↗ |
CARUSO JAMES V Chief Executive Officer | May 7, 2026 | Purchase | 8,680 | $2.88 | $25.0K | 20.3K | Form 4 ↗ |
NEIS JOHN director | Dec 12, 2025 | Sale | 198 | $3.70 | $731.986 | 10 | Form 4 ↗ |
CARUSO JAMES V Chief Executive Officer | Jul 2, 2025 | Purchase | 10,000 | $4.99 | $49.9K | 11.6K | Form 4 ↗ |
CARUSO JAMES V Chief Executive Officer | Jul 2, 2025 | Purchase | 10,000 | $5.25 | $52.5K | 10.0K | Form 4 ↗ |
Longcor Jarrod Chief Operating Officer | Jul 2, 2025 | Purchase | 10,000 | $4.99 | $49.9K | 12.8K | Form 4 ↗ |
Longcor Jarrod Chief Operating Officer | Jul 2, 2025 | Purchase | 10,000 | $5.25 | $52.5K | 10.0K | Form 4 ↗ |
Kolean Chad J Chief Financial Officer | Jul 2, 2025 | Purchase | 5,000 | $4.99 | $24.9K | 6.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cellectar Biosciences, Inc. (CLRB) is primarily owned by institutional investors, who hold approximately 13.1% of total shares outstanding. Company insiders own approximately 5.67%, while retail and public investors account for the remaining 81.27%.
The largest institutional shareholder of Cellectar Biosciences, Inc. is BARCLAYS PLC, holding approximately 120,497 shares — equal to 7.49% of outstanding shares — as of September 30, 2025.
A total of 22 institutional investors currently hold CLRB stock, with a combined institutional value of approximately $1,908,236 as of the most recent 13F filing period.
Frequently asked questions
CLRB ownershipCellectar Biosciences, Inc. (CLRB) is primarily owned by institutional investors, who hold approximately 13.1% of shares. The largest shareholder is BARCLAYS PLC with a 7.49% stake. Company insiders hold 5.67%. Data sourced from SEC Form 13F as of September 30, 2025.